AbbVie raises profit forecast, but Humira concerns weigh on shares

AbbVie Inc’s better-than-expected quarterly profit and revenue and raised full-year earnings forecast failed to impress investors who focused on the uncertainty around its blockbuster drug Humira as it struggles against cheaper rivals.